Skip to content
2000
Volume 4, Issue 1
  • ISSN: 2211-5420
  • E-ISSN: 2211-5439

Abstract

Cell therapy for the failing heart has advanced in distinct phases or era with a first transition from dynamic to cellular cardiomyoplasty. Currently, the quest is to find the optimal replacement cell type or to engineer a substitute for the dysfunctional scarred tissue. Cell therapies still require major refinements before they can—in a truly therapeutic manner—aid the suffering myocardium that fails either to adequately support contraction or to permit dilatation. Here, we outline the road so far and provide an insight into current and future challenges that await resolving.

Loading

Article metrics loading...

/content/journals/cte/10.2174/2211542004666150305235238
2015-04-01
2025-12-18
Loading full text...

Full text loading...

/content/journals/cte/10.2174/2211542004666150305235238
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test